Low-Dose Nivolumab with or without Ipilimumab as Adjuvant Therapy Following the Resection of Melanoma Metastases: A Sequential Dual Cohort Phase II Clinical Trial

Low-Dose Nivolumab with or without Ipilimumab as Adjuvant Therapy Following the Resection of Melanoma Metastases: A Sequential Dual Cohort Phase II Clinical Trial

Background: Optimal dosing and duration of adjuvant treatment with PD-1 and CTLA-4 immune checkpoint inhibitors have not been established. Prior to their regulatory approval we investigated a low-dose regimen of nivolumab with or without ipilimumab in a sequential dual-cohort phase II clinical trial...

Full description

Bibliographic Details
Main Authors: Julia Katharina Schwarze, Soizic Garaud, Yanina J. L. Jansen, Gil Awada, Valérie Vandersleyen, Jens Tijtgat, Alexandre de Wind, Paulus Kristanto, Teofila Seremet, Karen Willard-Gallo, Bart Neyns
Format: Article
Language:English
Published: MDPI AG 2022-01-01
Series:Cancers
Subjects:
adjuvant
melanoma
immunotherapy
low dose
nivolumab
ipilimumab
Online Access:https://www.mdpi.com/2072-6694/14/3/682

Internet

https://www.mdpi.com/2072-6694/14/3/682

Similar Items